Navigation Links
OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Date:11/15/2012

SAN DIEGO, Nov. 15, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress. This preliminary interim analysis of 13 out of 25 patients supports key findings from a Phase I trial suggesting that ImmunoPulse is able to induce regression or stabilization of distant untreated metastases following a single cycle of treatment.

(Logo:  http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)   

A total of up to 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma will be enrolled in this Phase II, single-arm, open-label and multi-center study. The trial was designed to assess local and distant objective response following treatment of cutaneous melanoma lesions with ImmunoPulse. As per the protocol, a preliminary interim analysis was scheduled upon completion of 50 percent enrollment in the study.

The purpose of the analysis was to confirm safety and efficacy observed in the Phase I study. At the time of this preliminary interim analysis, 13 patients were enrolled and treated. Thirteen subjects were evaluable at Day 39, nine at Day 90, and two at Day 180. Ninety-five percent of treated lesions demonstrated response at Day 39 (5 percent progressive disease, 14 percent stable disease (SD), 42 percent partial response (PR), 39 percent complete response (CR)). All treated lesions at Day 90 (5 percent SD, 50 percent PR, 45 percent CR), and at Day 180 (33 percent PR, 67 percent CR) demonstrated a response. At Day 180, two subjects were evaluable for the primary endpoint of objective overall respons
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
2. OncoSec to Present at Upcoming Healthcare and Investor Conferences
3. OncoSec Granted New Patent from China
4. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
5. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
6. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
7. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
8. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
9. OncoSec Medical Issues Letter to Shareholders
10. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
11. Patient and Disability Groups Support Bill to Begin Market Pricing System for Home Medical Equipment in Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Research and ... of the  "2015 Strategies in the Global ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... of the orthopedics market, including forecasts for ... categories. , ,In addition, the report presents ...
(Date:5/27/2015)... Research and Markets ( ... the  "North America Mammography Market - Growth, ...  report to their offering.      ... detailed type of imaging that customs a ... mammography exam, called a mammogram, is used ...
(Date:5/27/2015)... 27, 2015 OpportunityAnalyzer: Sepsis - Opportunity Analysis ... suffer from a series of diverse complications arising from ... blood or tissues, which cause a rapidly progressing hyperactive ... rates near 50% depending on disease severity. The syndrome ... of the global marketplace, which for the purposes of ...
Breaking Medicine Technology:Global Orthopedics Market Strategies 2015 2North America Mammography Market - Growth, Trends And Forecasts (2014 - 2019) 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4
... 2012   CANTEL MEDICAL CORP. (NYSE:CMN) announced today ... presenting at the Needham & Company, LLC  14th Annual ... AM ET on Wednesday, January 11, 2012 at The ... session immediately following the presentation. In addition, Mr. Krakauer ...
... 4, 2012 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), ... focused on cardiac and vascular surgery, announced today that ... position of Vice President, Research and Development; and David ... President, Market Development Surgical Adhesives and Starch Medical Relations.  ...
Cached Medicine Technology:CryoLife Enhances Management Team with Promotions 2CryoLife Enhances Management Team with Promotions 3CryoLife Enhances Management Team with Promotions 4CryoLife Enhances Management Team with Promotions 5
(Date:5/27/2015)... California (PRWEB) May 27, 2015 Western ... marked by a few historic firsts -- and one ... the Pasadena Civic Center marked the first time the ... the first time a Graduate College of Biomedical Sciences ... of the Pacific (COMP). , The university’s fifth and ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 “We are ... Schuller, MD, executive vice president and vice president of ... grant makes possible allows us to provide comprehensive care ... our community.” , SSCHC provides clinical care and behavioral ... 35,000 people in 2014, many of whom took advantage ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 While hair ... hair loss, a new pilot study conducted by a ... Surgery (ISHRS) has found hair follicle grafting can help ... research was partially funded by ISHRS, which offers research ... to hair restoration. , In the past decade, ...
(Date:5/27/2015)... 2015 NOVAtime Technology, Inc. ( ... solutions for enterprise organizations, announced today that SanMar ... automate its time, attendance and point tracking processes ... the United States. , Family-owned since 1971, ... 21 retail, private label, and mill brands. SanMar ...
(Date:5/27/2015)... ABILENE, Texas (PRWEB) May 27, 2015 ... addition of three FDA-approved dermal filler treatments in Abilene, ... designed to reduce the appearance of glabellar lines, better ... lines. Belotero Balance® is designed to treat smoker’s ... mouth to the chin, while Radiesse® improves the appearance ...
Breaking Medicine News(10 mins):Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 2Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 3Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 4Health News:WesternU Commencement Celebrates Achievements of Graduates and Founding President 5Health News:Sixteenth Street Community Health Centers To Expand Primary Care and Behavioral Health Services Through $1 Million Grant From Aurora's Better Together Fund 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 2Health News:SanMar Corporation Successfully Implemented NOVAtime Workforce Management Solution across 9 locations 3Health News:The MedSpa at Hendrick Introduces Xeomin®, Belotero Balance® and Radiesse® Injectables 2
... The California Alliance for Inclusive Communities (CAIC) has recently ... 374. They join the majority of state and national ... is an advocacy group that works on behalf of ... ,Just as a new national AP/Ipsis poll ...
... new report released today by the Pharmaceutical Research and ... testing 277 medicines for two of the three leading ... and stroke. The medicines are currently in clinical trials ... (FDA). ,'Heart disease and stroke are still ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... effects on cardiometabolic risk factors beyond those expected from ... may not be due to the drug itself, reports ... Therapeutics Bulletin (DTB). ,Advertisements for rimonabant ... that an estimated 50% of the effects on ...
... year the last day of May is celebrated as the ... World Health Organization to wag a warning finger at the ... This year the focus is on 100% smoke free ... to tobacco. There is also an effort to highlight the progress ...
... smokers today by declaring the site of the Beijing Olympics a ... Olympic venues and restaurants," The Telegraph quoted Zhang Jianshu, a city ... issue can raise has already been seen at the stadiums for ... by security guards to stop construction workers taking a cigarette break ...
Cached Medicine News:Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2Health News:Stop Smoking, Start Living: World No Tobacco Day 2Health News:Stop Smoking, Start Living: World No Tobacco Day 3Health News:Stop Smoking, Start Living: World No Tobacco Day 4Health News:China Bans Smoking at Olympics 2
For the qualitative detection of Hepatitis B surface Antigen (HBsAG) in human serum, plasma and whole blood specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of luteinising Hormone (LH) in urine specimens...
For the qualitative detection of group A Streptococcal antigen from throat swabs...
Medicine Products: